Literature DB >> 22076426

Bone development in children and adolescents with PKU.

A B Mendes1, F F Martins, W M S Cruz, L E da Silva, C B M Abadesso, G T Boaventura.   

Abstract

INTRODUCTION: Individuals with phenylketonuria (PKU, OMIM 261600) have shown bone disease from childhood. Factors such as non-adherence to treatment, nutritional inadequacy, and high phenylalanine levels are associated with bone disease in several studies. This research aimed to describe the impact of dietary factors (consumption of energy, protein, calcium, phosphorus, and phenylalanine), and the control of plasma phenylalanine levels on bone age (BA) and bone mineral density (BMD).
METHODOLOGY: Thirteen patients of both genders, from 8 to 16 years old participated in this study. Control data were collected of phenylalanine levels, food frequency and record, hand and fist X-rays, and spinal bone densitometry.
RESULTS: In children group (CG), individuals non-adherent to diet (NAD) consumed lower amounts of calcium (472 ± 100 mg/day) and energy (1743 ± 486 Kcal); they had higher rates of phenylalanine (564 ± 94 μmol/L) in blood, intake phenylalanine (701 ± 334 mg/g), and higher protein intake from free foods (14 ± 6.67 g/day); bone age (BA) values higher than the chronological age (CA) and less BMD values (-0.7 ± 1.6 SD) also were verified. In adolescent group (AG, N = 8) of NAD, values were lower for energy intake (1379 ± 258 Kcal), calcium (801 ± 152 mg/day), phosphorus (657 ± 102 mg/day), food protein (25 ± 7.6 g/day), and intake phenylalanine (1067 ± 382 mg/day) than recommended. Higher levels of plasma phenylalanine (851 ± 244 μmol/L), bone age greater than chronological age and lower BMD values (-2.4 ± -2.5 SD) were observed.
CONCLUSION: The results suggest effects on BA and on BMD, in both children and adolescent groups. The bone development is expressed differently in children and adolescents. The non-adherence to the diet verified in both groups and the consequent imbalance in the nutrients intake involved in bone metabolism suggest that these factors influence the failure to thrive in children and reduced bone mineralization in adolescents.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22076426     DOI: 10.1007/s10545-011-9412-7

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  16 in total

1.  Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis.

Authors:  H K Genant; C Cooper; G Poor; I Reid; G Ehrlich; J Kanis; B E Nordin; E Barrett-Connor; D Black; J P Bonjour; B Dawson-Hughes; P D Delmas; J Dequeker; S Ragi Eis; C Gennari; O Johnell; C C Johnston; E M Lau; U A Liberman; R Lindsay; T J Martin; B Masri; C A Mautalen; P J Meunier; N Khaltaev
Journal:  Osteoporos Int       Date:  1999       Impact factor: 4.507

2.  Living with phenylketonuria: perspectives of patients and their families.

Authors:  C Bilginsoy; N Waitzman; C O Leonard; S L Ernst
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

3.  Bone mineral density in patients with phenylketonuria.

Authors:  J Zeman; M Bayer; J Stepán
Journal:  Acta Paediatr       Date:  1999-12       Impact factor: 2.299

4.  Attributes of the radiographic standard of reference for the National Health Examination Survey.

Authors:  S I Pyle; A M Waterhouse; W W Greulich
Journal:  Am J Phys Anthropol       Date:  1971-11       Impact factor: 2.868

5.  Nutrient intake and food consumption of adolescents and young adults with phenylketonuria.

Authors:  B Schulz; H J Bremer
Journal:  Acta Paediatr       Date:  1995-07       Impact factor: 2.299

6.  New approach to osteopenia in phenylketonuric patients.

Authors:  B Pérez-Dueñas; F J Cambra; M A Vilaseca; N Lambruschini; J Campistol; J A Camacho
Journal:  Acta Paediatr       Date:  2002       Impact factor: 2.299

7.  Recommendations for protein and energy intakes by patients with phenylketonuria.

Authors:  P B Acosta
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

Review 8.  The truth of treating patients with phenylketonuria after childhood: the need for a new guideline.

Authors:  F J van Spronsen; P Burgard
Journal:  J Inherit Metab Dis       Date:  2008-08-12       Impact factor: 4.982

Review 9.  Growth and body composition in children with classical phenylketonuria: results in 34 patients and review of the literature.

Authors:  M Huemer; C Huemer; D Möslinger; D Huter; S Stöckler-Ipsiroglu
Journal:  J Inherit Metab Dis       Date:  2007-07-11       Impact factor: 4.982

10.  Peak bone mass in patients with phenylketonuria.

Authors:  D Modan-Moses; I Vered; G Schwartz; Y Anikster; S Abraham; R Segev; Ori Efrati
Journal:  J Inherit Metab Dis       Date:  2007-03-08       Impact factor: 4.750

View more
  10 in total

1.  PKU patients on a relaxed diet may be at risk for micronutrient deficiencies.

Authors:  C Rohde; A von Teeffelen-Heithoff; A G Thiele; M Arelin; U Mütze; C Kiener; J Gerloff; C Baerwald; S Schultz; C Heller; A S Müller; W Kiess; S Beblo
Journal:  Eur J Clin Nutr       Date:  2013-11-20       Impact factor: 4.016

2.  Glycomacropeptide Safety and Its Effect on Gut Microbiota in Patients with Phenylketonuria: A Pilot Study.

Authors:  Chiara Montanari; Camilla Ceccarani; Antonio Corsello; Juri Zuvadelli; Emerenziana Ottaviano; Michele Dei Cas; Giuseppe Banderali; Gianvincenzo Zuccotti; Elisa Borghi; Elvira Verduci
Journal:  Nutrients       Date:  2022-04-29       Impact factor: 6.706

Review 3.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

Review 4.  Bone health in phenylketonuria: a systematic review and meta-analysis.

Authors:  Serwet Demirdas; Katie E Coakley; Peter H Bisschop; Carla E M Hollak; Annet M Bosch; Rani H Singh
Journal:  Orphanet J Rare Dis       Date:  2015-02-15       Impact factor: 4.123

5.  Bone Mineralization and Calcium Phosphorus Metabolism.

Authors:  María Luz Couce; Miguel Saenz de Pipaon
Journal:  Nutrients       Date:  2021-10-21       Impact factor: 5.717

6.  Uncovering Hidden Mechanisms of Different Prescriptions Treatment for Osteoporosis via Novel Bioinformatics Model and Experiment Validation.

Authors:  Yujie Liu; Qinwen Liu; Chuanhui Yin; Yi Li; Jie Wu; Quanlin Chen; Hailang Yu; Aiping Lu; Daogang Guan
Journal:  Front Cell Dev Biol       Date:  2022-02-08

7.  Burden of phenylketonuria in Latin American patients: a systematic review and meta-analysis of observational studies.

Authors:  A L S Pessoa; A M Martins; E M Ribeiro; N Specola; A Chiesa; D Vilela; E Jurecki; D Mesojedovas; I V D Schwartz
Journal:  Orphanet J Rare Dis       Date:  2022-07-30       Impact factor: 4.303

8.  Development of newborn screening connect (NBS connect): a self-reported patient registry and its role in improvement of care for patients with inherited metabolic disorders.

Authors:  Yetsa Osara; Kathryn Coakley; Aishwarya Devarajan; Rani H Singh
Journal:  Orphanet J Rare Dis       Date:  2017-07-19       Impact factor: 4.123

9.  Sex differences in body composition and bone mineral density in phenylketonuria: A cross-sectional study.

Authors:  Bridget M Stroup; Karen E Hansen; Diane Krueger; Neil Binkley; Denise M Ney
Journal:  Mol Genet Metab Rep       Date:  2018-02-03

10.  Bone mineral density is within normal range in most adult phenylketonuria patients.

Authors:  Charlotte M A Lubout; Francisco Arrieta Blanco; Katarzyna Bartosiewicz; François Feillet; Maria Gizewska; Carla Hollak; Johanna H van der Lee; François Maillot; Karolina M Stepien; Margreet A E M Wagenmakers; Mendy M Welsink-Karssies; Francjan J van Spronsen; Annet M Bosch
Journal:  J Inherit Metab Dis       Date:  2020-02-06       Impact factor: 4.982

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.